The Medical Letter on Drugs and Therapeutics
FROM
ISSUE
1454
Antithrombotic Drugs
Subscribers: Log in to read full article.  Not a subscriber?  Subscribe or purchase article.
Revised 11/12/14: A paragraph on dipyridamole has been added to the first page (after aspirin).

Antiplatelet drugs are the drugs of choice for prevention and treatment of arterial thrombosis. Anticoagulants are the drugs of choice for prevention and treatment of venous thromboembolism and for prevention of cardioembolic events in patients with atrial fibrillation.

ANTIPLATELET DRUGS

Antiplatelet drugs are used mainly for acute coronary syndrome (ACS), which includes unstable angina/non-ST-elevation myocardial infarction (UA/NSTEMI), ST-elevation myocardial infarction (STEMI), and percutaneous coronary intervention (PCI).

ASPIRIN — Aspirin acetylates cyclooxygenase-1, blocking thromboxane synthesis and inhibiting platelet activation and aggregation for the life of the platelet (up to 10 days). Aspirin prophylaxis reduces the incidence of myocardial infarction (MI) and/or death by 15-25% in patients with UA/NSTEMI, STEMI, or ischemic stroke, and in those undergoing PCI or a coronary ... more      

The Medical Letter is a subscriber-funded nonprofit organization that publishes critical appraisals of new prescription drugs and comparative reviews of drugs for common diseases.

Would you like to read the rest of this article?  Gain access below.

Subscribe
Subscriptions to The Medical Letter on Drugs and Therapeutics include:
  • Print version published and mailed biweekly (26 issues/year)
  • Unlimited online access to current and past issues (1988 - present)
  • Mobile App for iOS, Android, and Kindle Fire
  • FREE online per issue CME/CE
Purchase this article:
Title: Antithrombotic Drugs
Article code: 1454a
 Electronic, downloadable article - $45
Gain access through your organization
Ask your librarian to consider an Institutional Subscription to The Medical Letter.
Recommend to your librarian